Preventing neuronal death is a priority for treating neurological diseases. However, therapies that inhibit pathological neuron loss could promote tumorigenesis by preventing the physiological death of cancerous cells. To avert this, we targeted the transcriptional upregulation of p21 waf1/cip1 (p21), an endogenous tumor suppressor with neuroprotective and pro-regenerative activity. We identified potential p21 indcuers by screening a FDA-approved drug and natural product small molecule library against hippocampal HT22 cells stably expressing a luciferase reporter driven by the proximal 60 bp of the p21 promoter, and tested them for neuroprotection from glutathione depletion mediated oxidative stress, and cytotoxicity to cancer cell lines (DLD-1, Neuro-2A, SH-SY5Y, NGP, CHLA15, CHP212, and SK-N-SH) in vitro. Of the p21 inducers identified, only ciclopirox, a hypoxia-inducible factor prolyl-4-hydroxylase (HIF-PHD) inhibitor, simultaneously protected neurons from glutathione depletion and decreased cancer cell proliferation at concentrations that were not basally toxic to neurons. We found that other structurally distinct HIF-PHD inhibitors (desferrioxamine, 3,4-dihydroxybenzoate, and dimethyloxalyl glycine) also protected neurons at concentrations that killed cancer cells. HIF-PHD inhibitors stabilize HIF transcription factors, mediating genetic adaptation to hypoxia. While augmenting HIF stability is believed to promote tumorigenesis, we found that chronic HIF-PHD inhibition killed cancer cells, suggesting a protumorigenic role for these enzymes. Moreover, our findings suggest that PHD inhibitors can be used to treat neurological disease without significant concern for cell-autonomous tumor promotion.
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Introduction
Therapeutics aimed at preserving neurons, preventing secondary apoptosis, and promoting regeneration in chronic neurodegenerative conditions will require long-term administration. As these agents may directly modulate cell survival or cell death pathways, they pose the risk of increasing tumor formation and carcinogenesis. To overcome this potential complication, we have conducted an unbiased screen for small molecules that upregulate the transcription of p21 waf1/cip1 (p21 hereafter), a target which has been associated with neuronal protection and suppression of tumor growth.
p21 is a member of the Cip/Kip family of cyclin-dependent kinase (Cdk) inhibitors that negatively modulates the cell cycle by binding and inhibiting cyclin-Cdk complexes or blocking DNA synthesis by binding the proliferating cell nuclear antigen. Induction or ectopic expression of p21 can inhibit mitotic cell proliferation and cause the terminal differentiation of some cell types. As a transcriptional target of p53, p21 mediates cell cycle arrest following DNA damage. As such, p21 is an important regulator of proliferation during development, differentiation, and tumorigenesis (Gartel and Radhakrishnan, 2005) . Paradoxically, p21 can suppress apoptosis by stalling the cell cycle to allow DNA repair before critical transitions, and, independent of Cdk inhibition, can directly block proapoptotic effectors in the cytosol such as apoptosis signal-regulating kinase 1 (Gartel and Tyner, 2002) .
p21 has been reported to prevent apoptosis in cell cycle-dependent and -independent models of neuron death. Nerve growth factor (NGF) deprivation of sympathetic neurons causes apoptosis secondary to cell cycle reentry, which can be blocked by overexpressing p21 (Park et al., 1997) . As markers of aberrant cell cycle activation are expressed by the vulnerable neurons in many neurological diseases (i.e., stroke,
